view more →
410 Medical is dedicated to developing innovative products that help emergency clinicians provide better care for critically ill patients.
view more →
AN2 is a biopharmaceutical company focused on developing novel medicines. IPO in March 2022 (NASDAQ: ANTX)
view more →
AtaCor Medical is developing a novel extracardiac pacing system that does not require leads or hardware to be placed inside or onto the heart.
view more →
Avivomed engages in developing neuromodulation therapy intended to treat unmet clinical needs.
view more →
CVRx has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. IPO in June 2021 (NASDAQ: CVRX).
view more →
Engages patients and families in a personalized way to initiate discussions on end-of-life care planning. Acquired by Aledade in January 2022.
view more →
RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke.
view more →
SafeRide’s technology provides end-to-end data transparency while improving patient experience, population health, and program efficiency.
view more →
Shattuck Labs is a clinical-stage biotechnology company for the treatment of cancer and autoimmune disease. IPO in October 2020 (NASDAQ: STTK)
view more →
The company’s lead drug has potential to be a game-changer in the treatment of HITT. Acquired by Cadrenal Therapeutics 2025
view more →
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. IPO in January 2022 (NASDAQ: VIGL). Acquired by Sanofi in 2025.
